T-cell receptor-MHC-Antigen complex and Pattern Recognition Receptors (BCG-mediated) (TCR-MHC-PRR)

The target complex represents the functional interface between the innate and adaptive immune systems during Bacillus Calmette-Guérin (BCG) immunotherapy, primarily utilized for non-muscle invasive bladder cancer (NMIBC). It involves the formation of an immune synapse where T-cell receptors (TCRs) recognize patient-specific tumor-associated antigens (neoantigens) presented by Major Histocompatibility Complex (MHC) molecules on the surface of antigen-presenting cells or urothelial cells (Source: PMID 29651115). Simultaneously, BCG acts as a potent agonist for innate pattern-recognition receptors (PRRs), most notably Toll-like receptors 2 and 4 (TLR2/4), which triggers the release of Th1-type cytokines such as IL-12 and IFN-gamma (Source: PMID 24561244). This dual signaling mechanism is essential for the recruitment and activation of cytotoxic CD8+ T cells and natural killer (NK) cells to the bladder wall. The resulting inflammatory microenvironment facilitates the targeted destruction of malignant cells and establishes long-term immunological memory to prevent tumor recurrence. Therapeutic success is highly dependent on the integrity of the MHC-TCR interaction and the robust activation of the PRR-mediated innate response.

Other names

BCG-induced immune synapseTCR-pMHC-TLR complexBCG-mediated immune activationImmune synapse between tumor antigen-MHC and TCR

BCG stimulates innate pattern recognition receptors (TLR2/4) to induce a pro-inflammatory environment that promotes the formation of an immune synapse between T-cell receptors and tumor-antigen-MHC complexes, leading to targeted tumor cell destruction.